Difference between revisions of "Part:BBa K4165148"

(→‎Usage and Biology)
(→‎Usage and Biology)
 
Line 10: Line 10:
  
 
<p style=" font-weight: bold; font-size:14px;"> IC<sub>50</sub> = 1.1 μM. </p>
 
<p style=" font-weight: bold; font-size:14px;"> IC<sub>50</sub> = 1.1 μM. </p>
 +
  
 
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
 
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>

Latest revision as of 14:04, 11 October 2022


W-MINK Peptide

A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.

Usage and Biology

W-MINK is a peptide (DVWMINKKRK), acquired by mirror image phage display to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. W-MINK can bind to PHF* in a mean that can disrupt the interaction between fibrils and consequently reduce the aggregates.

IC50 = 1.1 μM.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

W-MINK is modeled by AlphaFold2, Apptest, ITASSER and RosettaFold, best model obtained from AlphaFold2 



                            Figure 1.: Predicted 3D structure of Synthetic peptide W-MINK.


Table 1: Quality assessment parameters of W-MINK model.

References

1. Seidler, P. M., Boyer, D. R., Rodriguez, J. A., Sawaya, M. R., Cascio, D., Murray, K., ... & Eisenberg, D. S. (2018). Structure-based inhibitors of tau aggregation. Nature chemistry, 10(2), 170-176.